Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Prostatic Neoplasms 24 Neoplasm Metastasis 7 Neoplasms 5 Prostate Cancer Metastatic 4 Carcinoma, Transitional Cell 4 Recurrence 3 Urinary Bladder Neoplasms 2 Stomach Neoplasms 2 Squamous Cell Carcinoma of Head and Neck 2 Carcinoma, Squamous Cell 2 Carcinoma, Non-Small-Cell Lung 2 Solid Cancer 1 Small Cell Lung Carcinoma 1 Penile Neoplasms 1 Ovarian Neoplasms 1 Nonseminomatous germ cell tumor 1 Neoplastic Cells, Circulating 1 Metastatic Castration-resistant Prostate Cancer 1 Malignant Solid Tumor - Malignant Nervous System Neoplasm 1 Lymphadenopathy 1 Liposarcoma 1 Hormone Refractory Prostate Cancer 1 Head and Neck Neoplasms 1 Glioblastoma 1 Breast Neoplasms 1 Bone Metastatic Prostate Cancer 1 Advanced Solid Tumor 1

Interventions

Doxorubicin 14 Radiotherapy 10 Ifosfamide 10 Trabectedin 7 pazopanib 4 Imatinib Mesylate 3 Filgrastim 3 Etoposide 3 Cyclophosphamide 3 Chemotherapy, Adjuvant 3 temsirolimus 2 romidepsin 2 ribociclib 2 pegfilgrastim 2 eribulin 2 cixutumumab 2 brigimadlin 2 belinostat 2 Vincristine 2 Sunitinib 2 Radiotherapy, Conformal 2 Gemcitabine 2 Epirubicin 2 Dexamethasone 2 Dactinomycin 2 Carboplatin 2 soblidotin 1 sitravatinib 1 siremadlin 1 selinexor 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Completed × Liposarcoma × cabazitaxel × Clear all

NCT01913652 2021-09-14

Ph II Cabazitaxel DD Liposarcoma

European Organisation for Research and Treatment of Cancer - EORTC

Phase 2 Completed

Liposarcoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡